Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.

NCT: NCT03311451 · ACTIVE_NOT_RECRUITING

NCT IDNCT03311451
StatusACTIVE_NOT_RECRUITING
Start Date2023-01-16
Completion2026-12-18
SponsorMerit Medical Systems, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The primary objective is to determine the safety and efficacy of the C2 CryoBalloon 180 Ablation System ("CryoBalloon 180") used at decreasing doses in ablation naïve patients with low- or high-grade dysplastic Barrett's Esophagus (BE) or with residual BE after resection of dysplasia or early adenocarcinoma.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑